Enable Injections Inc. said today that it closed a $30 million Series A round to bring its large-volume injector to market.
The Cincinnati, Ohio-based company’s Enable Injector adheres to a patient’s body and delivers biologic doses as large as 50 milliliters. It can be used at work or at home, providing an alternative to costly intravenous infusions in a healthcare setting.
The round was led by ORI Healthcare Fund, with CincyTech, Cincinnati Children’s Hospital, CintriFuse and Ohio Innovation Fund also participating in the financing.
Biologics, which make up the majority of top selling medications for many cancers and autoimmune diseases, are often required in doses exceeding 5 milliliters, according to Enable Injections. The typical syringe dose is 1 milliliter.